2023-509316-28-00已完成1 期
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants
Sanofi-Aventis Recherche & Developpement1 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2024年4月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 128
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Sciences and Operations
Scientific
Sanofi-Aventis Recherche & Developpement
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
招募中
1 期
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy ParticipantsNCT07271693Hoffmann-La Roche128
招募中
1 期
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
招募中
1 期
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma2023-506993-11-00AbbVie Deutschland GmbH & Co. KG22